Elexacaftor–tezacaftor–ivacaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in children aged 2 to 5 [TSID10767]

Status:

Topic selection

Technology type:

Medicine

Decision:

Not selected

Reason for decision:

Not eligible for Health Technology Evaluation guidance

Further information:

It has been concluded that this licence extension will be incorporated into the Multi-Technology Appraisal of Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [ID3834]. For more information on ID3834, please email [email protected].

ID number:

10767

Project Team

Project lead

Abigail Stephens

Email enquiries

If you have any queries please email [email protected]

For further information on how we select topics for development, please see our page about prioritising our guidance topics